Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

984 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. John T, et al. Among authors: tsuboi m. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. J Thorac Oncol. 2023. PMID: 37236398 Free article. Clinical Trial.
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. Among authors: tsuboi m. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
Tsuboi M, Herbst RS, Wu YL. Tsuboi M, et al. N Engl J Med. 2023 Oct 5;389(14):1342. doi: 10.1056/NEJMc2309385. N Engl J Med. 2023. PMID: 37792623 No abstract available.
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
Mirza M, Shrivastava A, Matthews C, Leighl N, Ng CSH, Planchard D, Popat S, Rotow J, Smit EF, Soo R, Tsuboi M, Yang F, Stiles B, Grohe C, Wu YL. Mirza M, et al. Among authors: tsuboi m. Front Oncol. 2024 Jan 23;13:1330468. doi: 10.3389/fonc.2023.1330468. eCollection 2023. Front Oncol. 2024. PMID: 38322280 Free PMC article.
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Matsuda A, Yamaoka K, Kunitoh H, Seto T, Tsuboi M, Ohira T, Maruyama R, Okamoto H, Kubota K. Matsuda A, et al. Among authors: tsuboi m. Qual Life Res. 2023 Sep;32(9):2629-2637. doi: 10.1007/s11136-023-03424-y. Epub 2023 May 1. Qual Life Res. 2023. PMID: 37126140 Clinical Trial.
Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma.
Kagawa Y, Nakai T, Taki T, Hashimoto H, Tanaka Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Watanabe R, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Goto K, Ishii G. Kagawa Y, et al. Among authors: tsuboi m. Cancer Sci. 2023 Aug;114(8):3423-3432. doi: 10.1111/cas.15848. Epub 2023 Jun 1. Cancer Sci. 2023. PMID: 37264761 Free PMC article.
984 results